A carregar...
Measuring Cardiopulmonary Complications of Carfilzomib Treatment and Associated Risk Factors Using the SEER-Medicare Database
BACKGROUND. Carfilzomib improves survival in patients with relapsed myeloma. Given the strict eligibility criteria in the clinical trials, the actual frequency of cardiac (CAEs) and pulmonary adverse events (PAEs) and risk factors associated with these AEs in the general population needs to be estab...
Na minha lista:
| Publicado no: | Cancer |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6992490/ https://ncbi.nlm.nih.gov/pubmed/31721140 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.32601 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|